	US 12,078,638 B2
	Diagnostic and therapeutic methods for cancer
Priti Hegde, San Mateo, CA (US); and Mahrukh Huseni, Union City, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Jun. 8, 2022, as Appl. No. 17/835,418.
Application 17/835,418 is a division of application No. 16/545,177, filed on Aug. 20, 2019, granted, now 11,402,382.
Application 16/545,177 is a continuation of application No. PCT/US2018/020460, filed on Mar. 1, 2018.
Claims priority of provisional application 62/572,979, filed on Oct. 16, 2017.
Claims priority of provisional application 62/514,680, filed on Jun. 2, 2017.
Claims priority of provisional application 62/465,547, filed on Mar. 1, 2017.
Prior Publication US 2023/0082122 A1, Mar. 16, 2023
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/404 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)

CPC G01N 33/5748 (2013.01) [A61K 31/404 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01); C07K 16/22 (2013.01); C07K 16/2827 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)]

9 Claims

1. A method of treating an individual having a renal cell carcinoma (RCC), the method comprising:

(a) determining the expression levels of the following sets of genes in a tumor tissue sample from the individual prior to treatment with bevacizumab and atezolizumab:

T effector and IFNγ response (Teff) genes comprising CD8A, EOMES, PRF1, IFNG, and PD-L1; and

Myeloid inflammation-related (Myeloid) genes comprising IL6, CXCL1, CXCL2, CXCL3, CXCL8, and PTGS2;

wherein

(i) the mRNA expression levels of CD8A, EOMES, PRF1, IFNG, and PD-L1 in the tumor tissue sample are determined to be at or above reference expression levels of the genes; and

(ii) the mRNA expression levels of IL6, CXCL1, CXCL2, CXCL3, CXCL8, and PTGS2 in the tumor tissue sample are determined to be at or above reference expression levels of the genes, wherein the reference expression levels of the genes are the median expression levels of the genes determined in a population of individuals having RCC; and

(b) administering an effective amount of an anti-cancer therapy comprising bevacizumab and atezolizumab to the individual having (i) mRNA expression levels of CD8A, EOMES, PRF1, IFNG, and PD-L1 in the tumor tissue sample that are at or above the reference expression levels of the genes; and (ii) mRNA expression levels of IL6, CXCL1, CXCL2, CXCL3, CXCL8, and PTGS2 in the tumor tissue sample that are at or above the reference expression levels of the genes.